MX387961B - Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. - Google Patents
Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.Info
- Publication number
- MX387961B MX387961B MX2019003720A MX2019003720A MX387961B MX 387961 B MX387961 B MX 387961B MX 2019003720 A MX2019003720 A MX 2019003720A MX 2019003720 A MX2019003720 A MX 2019003720A MX 387961 B MX387961 B MX 387961B
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- parkinson
- methods
- compositions
- treating alzheimer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402357P | 2016-09-30 | 2016-09-30 | |
| PCT/US2017/054473 WO2018064559A1 (en) | 2016-09-30 | 2017-09-29 | Compositions and methods for treating alzheimer's disease and parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019003720A MX2019003720A (es) | 2019-09-19 |
| MX387961B true MX387961B (es) | 2025-03-19 |
Family
ID=61756894
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003720A MX387961B (es) | 2016-09-30 | 2017-09-29 | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. |
| MX2021014093A MX2021014093A (es) | 2016-09-30 | 2019-03-29 | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014093A MX2021014093A (es) | 2016-09-30 | 2019-03-29 | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10314798B2 (enExample) |
| EP (1) | EP3518914A4 (enExample) |
| JP (1) | JP2019529502A (enExample) |
| AR (1) | AR109760A1 (enExample) |
| AU (2) | AU2017337053B2 (enExample) |
| CA (1) | CA3037059A1 (enExample) |
| IL (1) | IL265656A (enExample) |
| MX (2) | MX387961B (enExample) |
| TW (1) | TWI753952B (enExample) |
| WO (1) | WO2018064559A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018064559A1 (en) | 2016-09-30 | 2018-04-05 | Biotie Therapies, Inc. | Compositions and methods for treating alzheimer's disease and parkinson's disease |
| EP4054537B1 (en) * | 2019-11-04 | 2023-06-07 | Cinclus Pharma Holding AB (publ) | Oral formulation of x842 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2368083A1 (en) * | 1999-04-06 | 2000-10-12 | Sepracor Inc. | Derivatives of venlafaxine and methods of preparing and using the same |
| US7323192B2 (en) * | 2001-09-28 | 2008-01-29 | Mcneil-Ppc, Inc. | Immediate release tablet |
| CA2552114A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
| US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| CN101119965B (zh) * | 2004-12-21 | 2012-09-26 | 弗·哈夫曼-拉罗切有限公司 | 萘满和茚满衍生物及其用途 |
| MX2008015843A (es) * | 2006-06-20 | 2009-01-09 | Hoffmann La Roche | Derivados de tetralina e indano y usos de los mismos. |
| FR2974102B1 (fr) * | 2011-04-13 | 2014-08-22 | Rhodia Operations | Composition polyamide stabilisee |
| WO2015173133A1 (en) * | 2014-05-12 | 2015-11-19 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| WO2018064559A1 (en) | 2016-09-30 | 2018-04-05 | Biotie Therapies, Inc. | Compositions and methods for treating alzheimer's disease and parkinson's disease |
-
2017
- 2017-09-29 WO PCT/US2017/054473 patent/WO2018064559A1/en not_active Ceased
- 2017-09-29 US US15/720,947 patent/US10314798B2/en not_active Expired - Fee Related
- 2017-09-29 AR ARP170102714A patent/AR109760A1/es unknown
- 2017-09-29 EP EP17857545.2A patent/EP3518914A4/en not_active Withdrawn
- 2017-09-29 JP JP2019517827A patent/JP2019529502A/ja active Pending
- 2017-09-29 CA CA3037059A patent/CA3037059A1/en not_active Abandoned
- 2017-09-29 TW TW106133810A patent/TWI753952B/zh not_active IP Right Cessation
- 2017-09-29 MX MX2019003720A patent/MX387961B/es unknown
- 2017-09-29 AU AU2017337053A patent/AU2017337053B2/en not_active Ceased
-
2019
- 2019-01-16 US US16/249,290 patent/US10973784B2/en not_active Expired - Fee Related
- 2019-03-27 IL IL265656A patent/IL265656A/en unknown
- 2019-03-29 MX MX2021014093A patent/MX2021014093A/es unknown
-
2021
- 2021-03-01 US US17/188,413 patent/US20210177783A1/en not_active Abandoned
- 2021-12-01 AU AU2021277698A patent/AU2021277698A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021277698A1 (en) | 2021-12-23 |
| MX2019003720A (es) | 2019-09-19 |
| MX2021014093A (es) | 2021-12-10 |
| US20180092868A1 (en) | 2018-04-05 |
| AU2017337053A1 (en) | 2019-04-04 |
| AU2017337053B2 (en) | 2021-09-02 |
| EP3518914A4 (en) | 2020-06-10 |
| TWI753952B (zh) | 2022-02-01 |
| US10973784B2 (en) | 2021-04-13 |
| US20210177783A1 (en) | 2021-06-17 |
| US20190142771A1 (en) | 2019-05-16 |
| WO2018064559A1 (en) | 2018-04-05 |
| US10314798B2 (en) | 2019-06-11 |
| AR109760A1 (es) | 2019-01-23 |
| TW201813638A (zh) | 2018-04-16 |
| CA3037059A1 (en) | 2018-04-05 |
| JP2019529502A (ja) | 2019-10-17 |
| IL265656A (en) | 2019-05-30 |
| EP3518914A1 (en) | 2019-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX377576B (es) | Formulaciones de pridopidina de liberación modificada. | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX387322B (es) | Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1). | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| MX378707B (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| PH12019500025A1 (en) | Cancer treatment combinations | |
| JP2015057451A5 (enExample) | ||
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| TR201816176T4 (tr) | Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler. | |
| MX383665B (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| JOP20190191A1 (ar) | وحدات شجرية علاجية | |
| PH12020551186B1 (en) | Sustained-release dosage forms of ruxolitinib | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| MX2018006247A (es) | Metodos para tratar la enfermedad de alzheimer y trastornos relacionados. | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| FI3445351T3 (fi) | Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |